Reduction of pressor effects of angiotensin I in man by synthetic nonapeptide (B.P.P. 9a  or SQ 20,881) which inhibits converting enzyme.
D000328:Adult; D000804:Angiotensin II / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D000806:Angiotensin-Converting Enzyme Inhibitors; D001794:Blood Pressure / Q000187:drug effects; D001920:Bradykinin / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy / Q000201:enzymology; D066298:In Vitro Techniques; D007275:Injections, Intravenous; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology* / Q000627:therapeutic use; D010455:Peptides / Q000494:pharmacology*; D011480:Protease Inhibitors; D013997:Time Factors; D014688:Venoms
D000806:Angiotensin-Converting Enzyme Inhibitors; D009842:Oligopeptides; D010455:Peptides; D011480:Protease Inhibitors; D014688:Venoms; D000804:Angiotensin II; D001920:Bradykinin